23 October 2025
EssilorLuxottica has announced its acquisition of health technology company, RetinAI, building on the group’s moves into the med-tech space.
The acquisition involves Ikerian AG, a health technology company that operates under the RetinAI brand, and specialises in artificial intelligence (AI) and data management in eye care.
RetinAI develops tools to collect, process, and grade large-scale retinal images and biomarker datasets.
The company’s platform, RetinAI Discovery, applies AI models to support the diagnosis and monitoring of disease progression, including age-related macular degeneration, glaucoma, and diabetic retinopathy. The platform is FDA cleared and CE-marked.
RetinAI also partners with pharmaceutical companies and research organisations that leverage proprietary real-world evidence to accelerate clinical studies and drug development.
Carlos Ciller, chairman and CEO of RetinAI (Ikerian AG), described joining EssilorLuxottica as a “defining moment” for the technology company, sharing: “This acquisition opens an exciting new chapter for our team and technology. From the start, we’ve believed in the power of data and AI to transform patient care.”
The global reach of EssilorLuxottica can help the company “bring that vision to life at an entirely new scale,” Ciller said, adding: “Together we’ll shape how technology drives better healthcare, sharper vision, and improved outcomes for patients.”
Francesco Milleri, chairman and CEO at EssilorLuxottica, said: “In the past year alone, we’ve made several bold moves in med-tech, all with the goal of building the most comprehensive, digitally enabled patient journey.”
With the AI-powered analytics of RetinAI, the company can turn “clinical data into insights that enable faster, more accurate diagnoses and more effective disease monitoring,” Milleri said.
Computer says go
From putting data in the hands of patients to predicting which children will develop high myopia, OT explores the potential of artificial intelligence technology for eye care
SWITCH event plans
EssilorLuxottica has also revealed plans for a new event exploring connected healthcare.
The Switch: Vision Innovation Summit by EssilorLuxottica for eye care professionals will include conversations from AI wearables to myopia innovation, and promote dialogue around data science and med-tech.
The event will be held over two sets of dates. The first, for partners in the Americas, will be held 9-11 March 2026 in Orlando, while customers in Europe, Middle East, Africa and Asia, will meet in Monte Carlo on 13-15 April.
Pictured (left-right): RetinAI founders Sandro De Zanet, chief scientific officer, Carlos Ciller, chief executive officer and chairman, and Stefanos Aposolopoulos, chief technology officer.
Comments (0)
You must be logged in to join the discussion. Log in